Neoadj Tx pt w/ ER-neg/HER2+ T3 LABC wanting breast conservation?
Neoadj Tx pt w/ ER-neg/HER2+ T3 LABC wanting breast conservation?
Which neoadjuvant treatment do you generally use for a patient with locally advanced (T3 lesion), ER-negative, HER2-positive breast cancer who desires breast conservation?
Consensus or Controversy, Issue 2: Clinical Investigators Provide Their Perspectives on Controversial Issues in the (Neo)adjuvant Treatment of HER2-Positive Breast Cancer
COCB13/2
TARGET AUDIENCE
This activity is intended for medical oncologists, hematologist-oncologists, hematology-oncology fellows, oncology nurses, radiation oncologists, breast/general surgeons and other healthcare practitioners involved in the management of breast cancer.
OVERVIEW OF ACTIVITY
Breast cancer remains the most frequently diagnosed type of cancer in women, with an estimated 234,580 new cases and 40,030 deaths in the United States in 2013. Advances in screening and prevention have resulted in a steady down-stage migration at the time of disease presentation, and the number of individuals living with breast cancer has increased substantially, as has the population “at risk” for recurrent disease.
Efficacy/tolerability of 2nd-line aflibercept vs bev beyond PD
Efficacy/tolerability of 2nd-line aflibercept vs bev beyond PD
How would you compare the efficacy of aflibercept to the use of bevacizumab on disease progression in the second-line setting?
How would you compare the side effects and tolerabilty of aflibercept to the use of bevacizumab on disease progression in the second-line setting?
Off protocol, approx no. of cases treated in past year with aflibercept; bev beyond PD
60 yo with obvious progression within a few months of FOLFOX/bev?
What systemic treatment would you most likely recommend for the following patients:
A 60-year-old patient with asymptomatic mCRC receives FOLFOX/bevacizumab but within a few months experiences obvious disease progression. The tumor is KRAS wild type.
Same as above, but the tumor is KRAS mutant?
Tx 60 yo KRAS wt tumor, obvious progression within a few months of FOLFOX/bev? A 75 yo pt?
75 yo with slow progression 1 y after FOLFOX/bev -> 5-FU/bev?
What systemic treatment would you most likely recommend for the following patients:
1st-line Tx 60 yo w/ unresectable mets 1 y after adj FOLFOX? Pt age at which you don’t want to use bev?
60 yo with slow progression 1 y after FOLFOX/bev -> 5-FU/bev?
What systemic treatment would you most likely recommend for the following patients:
Efficacy/tolerability of 2nd-line aflibercept vs bev beyond PD
Efficacy/tolerability of 2nd-line aflibercept vs bev beyond PD
How would you compare the efficacy of aflibercept to the use of bevacizumab on disease progression in the second-line setting?
How would you compare the side effects and tolerabilty of aflibercept to the use of bevacizumab on disease progression in the second-line setting?
60 yo with obvious progression within a few months of FOLFOX/bev?
60 yo with obvious progression within a few months of FOLFOX/bev?
What systemic treatment would you most likely recommend for the following patients:
A 60-year-old patient with asymptomatic mCRC receives FOLFOX/bevacizumab but within a few months experiences obvious disease progression. The tumor is KRAS wild type.
Same as above, but the tumor is KRAS mutant?
75 yo with slow progression 1 y after FOLFOX/bev -> 5-FU/bev?
75 yo with slow progression 1 y after FOLFOX/bev -> 5-FU/bev?
What systemic treatment would you most likely recommend for the following patients:
60 yo with slow progression 1 y after FOLFOX/bev -> 5-FU/bev?
60 yo with slow progression 1 y after FOLFOX/bev -> 5-FU/bev?
What systemic treatment would you most likely recommend for the following patients:
Consensus or Controversy, Issue 2: Clinical Investigators Provide Their Perspectives on Controversial Issues in the Management of Colorectal Cancer in the Second-Line Setting
COCCRC13/2
TARGET AUDIENCE
This activity is intended for medical oncologists, hematologist-oncologists, hematology-oncology fellows, oncology nurses, radiation oncologists, colorectal-general surgeons and other healthcare practitioners involved in the management of colorectal cancer.
OVERVIEW OF ACTIVITY
5MJCHEM2013/2/
OVERVIEW OF ACTIVITY
RS for 40 yo, 1.5-cm node+ (1 node) ER+ IDC? No. of MammaPrint® (70-gene signature) assays ordered in past 1 y?
RS for 40-year-old, 1.5-cm node+ (1 node) ER+ IDC? No. of MammaPrint® (70-gene signature) assays ordered in past 1 y?
Would you order an Oncotype DX assay for a 40-year-old premenopausal woman with a 1.5-cm, ER-positive, HER2-negative IDC and 1 positive node?
Approximately how many MammaPrint® assays have you ordered in the past year?